Member Info for Vander

Also be aware that a number of companies are making MSNs-They are easy to make- nuvec’s competitive advantage lies in the ‘spikes’ designed for plasmid dna by subcutaneous injection

Nigel should stop conflating rna with dna and should clearly present rna results - it goes without saying that rna and dna are completely different size and shaped molecules-although both nuclei acids. Moderna, curevac, bioNTech only deal in rna
Also Chemotherapeutic drug delivery is interesting but may have to be given intravenously with delivery of the payload to the exact site or risk off target toxicity ie much more research needed
Similarly for oral delivery. Hence need for scientific development team- lead by a collaborator- nanomerics will do for the timebeing

Astra Zeneca paid star pharma 2m usd for 2 yrs in 2015 for their dendrimer platform to develop AZD 0466
First in human trial announced in 2020- with 3m usd paid to starpharma

https://starpharma.com/news/462

It will be interesting to see development plans over the next year- to gain a big commercial partner the next step is large scale production and an effective animal disease model with a specific cargo- the increasing work on MSN’s on delivery of therapeutic drugs/ proteins/ nucleotides is positive but has still not got past small animal work in any area- it will take years to get a first in human trial but there is increasing promise. A big partner would pay development costs say £2m per year, increasing a bit with phase 1 trials- the big money comes with a marketed product. The UQ work Since 2016 focused on DNA delivery and the advantages of topographic design eg rambutan to enhance delivery- also other phd work on protein delivery and freeze drying- the oral delivery programme of nucleotides I am not aware of

Mayes- you are already all over Twitter- multiple fingers and multiple pies- why not keep your expert and unbiased ‘advice’ to yourself

Yep the key news would be announcement of a commercial collaborator
Nigel has approx 50 patents associated with the reformulation division

Leister:Here is the link to the current patent- snps for gene delivery from google patents

https://patents.google.com/patent/US20200392005A1/en?q=Silica+nanoparticles+&inventor=Michael+yu
Inventor Chengzhong (Michael) YuHao SongGraham WorrallLynn Donlon Current Assignee N4 Pharma Uk Ltd
Worldwide applications
2017 GB 2018 AU CN CA WO US EP
Application US16/764,267 events
2017-11-14
Priority to GBGB1718817.8A
2017-11-14
Priority to GB1718817.8
2018-11-14
Application filed by N4 Pharma Uk Ltd
2018-11-14
Priority to PCT/GB2018/053298
2020-08-08
Assigned to N4 PHARMA UK LIMITED
2020-10-16
Assigned to N4 PHARMA UK LIMITED
2020-12-17
Publication of US20200392005A1
2020-12-29
Assigned to N4 PHARMA UK LIMITED
Status
Pending

METHOD OF SYNTHESIS OF SILICA VESICLES AND USE THEREOF
Publication number: 20180193278
Abstract: The invention relates, in part, to a method of producing silica vesicles including under controlled conditions to thereby heavily influence the morphology and characteristics of the vesicles. The vesicles are shown to be effective as delivery agents for chemical and biological agents. They are also shown to be useful in methods of treatment and as components of an immunogenic composition.
Type: Application
Filed: December 19, 2014
Publication date: July 12, 2018
Applicant: The University of Queensland
Inventors: Chengzhong YU, Neena MITTER, Jun ZHANG

Bigears this is important information- it’s something fowler should address and clarify, otherwise his claims of expanding capacity at tema do not mean expanding Wsg revenue

It’s a shame that the incumbent Ghanaian scan company In their 5 airports have a contract until 2026.

Also the scanners were renewed in July 2019

The lack of news suggests (short term) results are at best mixed. Nigel is stymied in his wish to create momentum. Nuvec in common with multiple other highly specialised nanoparticles will take years to develop with multiple iterations whIch will be scientifically lead- it needs a commercial partner- development will be v slow otherwise imho

https://mobile.ghanaweb.com/GhanaHomePage/africa/Coronavirus-Sierra-Leone-capital-goes-into-2-weeks-lockdown-1163086

Also passengers require negative c19 test to fly

Myles is paying a few favours to his mates- he has changed his tune on Wsg- his previous assessment of fowler as a crook is inconsistent with today’s tweet

In tema the incumbent scanning contract holder remained in the pre-existing terminal (T2) and MPS subsumed the new T3 expansion. MPS simply claimed that they were not aware of the pre-existing contract- simples as they say in Russia

Russia recently donated 200 garbage trucks to Sierra Leone. They wish to supplant China’s influence, using BOT rather than unrepayable loans

http://www.thepatrioticvanguard.com/sierra-leone-russia-returns-with-a-big-splash

The current terminal will remain intact- however it is not clear that Wsg will be part of the expansion

The summa group may be the sole operator and concessionaire as in Niger

Close to a deal now- no one believed me- not even Balders or those scoffing traders-signed,sealed,
Delivered

Jimzi: Fowler has issued misleading RNS throughout his tenure imho. For example the ferry fiasco was not a 350m dollar project opportunity-dishonesty, compounded by botched delivery

The two discrepancies that you allege- inaccurate statement of unaudited revenue and self serving use of confidentiality rules are small parts of a bigger picture of dishonesty

However, They have rankled your lawyer’s sensibility- the LSE rules/process have been breached

Use of mRNA and/or oral delivery makes commercial sense but is a BIG divergence from their current evidence base Which is for plasmid
DNA and subcutaneous delivery

The first mentioned buying an additional asset in April 2018 but have lacked the funds until now

It’s important they diversify their product range- as mcnulty and other LTH know- N4p can provide some nasty surprises